Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Neurotherapeutic Agent Characterization and In vivo Efficacy Studies (R61/R33 Clinical Trial Not Allowed)
ID: 332081Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Award Range

$0 - $499K

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/332081

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAR-21-122.html
Timeline
    Description

    The National Institutes of Health (NIH) is offering the Innovation Grants to Nurture Initial Translational Efforts (IGNITE) program, aimed at funding pharmacodynamic and pharmacokinetic studies for the development of neurotherapeutic agents targeting neurological and neuromuscular disorders. This funding opportunity encourages innovative research that can lead to new therapeutic treatments, with a phased application approach (R61/R33) focusing first on the preparation and characterization of therapeutic agents, followed by in vivo efficacy studies. The initiative is critical for addressing unmet needs in neurology through rigorous scientific methodology and collaboration among diverse research teams. Interested applicants can apply for funding up to $499,000 per year, with a total cap of $750,000 over a three-year project period, and must submit their applications by October 21, 2024. For further information, applicants can contact the NIH OER Webmaster at FBOWebmaster@OD.NIH.GOV or visit the additional information link provided.

    Point(s) of Contact
    FBOWebmaster@OD.NIH.GOV
    Files
    Title
    Posted
    PAR-21-122-Full-Announcement.html
    PAR-21-122.html
    The Department of Health and Human Services, through the National Institutes of Health (NIH), announces the Innovation Grants to Nurture Initial Translational Efforts (IGNITE) to fund pharmacodynamic and pharmacokinetic studies aimed at developing neurotherapeutic agents for neurological and neuromuscular disorders. This initiative encourages innovative research that can lead to new therapeutic treatments. Applications must follow a phased approach (R61/R33), with the R61 phase focusing on preparation and characterization of therapeutic agents, while the R33 phase will carry out in vivo efficacy studies. Key eligibility criteria include institutions of higher education, non-profits, and for-profit organizations, among others. The funding opportunity requests applications that demonstrate strong biological rationale and have research designs including clear milestones for success. Applications involving human subjects or clinical trials are not permitted, as this funding is focused on preclinical research. Strict adherence to the NIH application guidelines is required, with proposals evaluated based on significance, investigator qualifications, innovation, approach, and environment. Funding is capped at $499,000 per year, with a total limit of $750,000 over the three-year project period. Overall, this opportunity aims to bolster research that addresses unmet needs in the field of neurology through rigorous scientific methodology and collaboration among diverse teams.
    Similar Opportunities
    Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Assay Development and Neurotherapeutic Agent Identification (R61/R33 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced the Innovation Grants to Nurture Initial Translational Efforts (IGNITE) program, aimed at funding research for assay development and neurotherapeutic agent identification for neurological disorders. This grant opportunity encourages the creation of in vitro and ex vivo assays and iterative screening to identify potential therapeutic agents, with a focus on projects that can transition to the Blueprint Neurotherapeutics Network. The initiative is particularly significant for advancing therapeutic options for underserved populations, with a funding limit of $499,000 per year and a total maximum of $750,000 over three years, while excluding any clinical trial-related research. Interested applicants can find more information and contact the NIH OER Webmaster at FBOWebmaster@OD.NIH.GOV, with applications due by October 21, 2024.
    Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Development and Validation of Model Systems to Facilitate Neurotherapeutic Discovery (R61/R33 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the Department of Health and Human Services, is offering funding opportunities under the Innovation Grants to Nurture Initial Translational Efforts (IGNITE) program, aimed at developing and validating animal models and human/animal ex vivo systems for neurological disorders. The primary objective is to enhance the translational relevance of these models to facilitate neurotherapeutic discovery, with applications invited for the R61/R33 phased award mechanism, which includes an R61 phase for model development and internal validation, followed by an R33 phase for external validation. This initiative is crucial for advancing neurological research and improving therapeutic efficacy predictions, with a total budget cap of $750,000 over three years for selected projects. Interested applicants must submit their proposals by October 21, 2024, and can reach out to the NIH OER Webmaster at FBOWebmaster@OD.NIH.GOV for any inquiries regarding the funding announcement.
    Drug Discovery For Nervous System Disorders (R21 Clinical Trials Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Drug Discovery For Nervous System Disorders (R21 Clinical Trials Not Allowed)" aimed at supporting innovative research in the identification and development of novel compounds for the prevention and treatment of nervous system disorders. This initiative encourages applications focused on early-stage research, particularly in the areas of small molecules, biotechnology products, and biologics, with an emphasis on projects that utilize machine learning and propose preclinical evaluations of candidate drugs. The funding amount available is up to $275,000, with a submission deadline of January 7, 2025. Interested applicants can find more information and submission guidelines at the provided NIH link or contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov for further inquiries.
    Joint NINDS/NIMH Exploratory Neuroscience Research Grant (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the Joint NINDS/NIMH Exploratory Neuroscience Research Grant (R21 Clinical Trial Optional) to support innovative and exploratory research projects in neuroscience. This grant aims to facilitate early-stage studies that assess novel avenues of investigation, particularly those that may involve significant risk but hold the potential for breakthroughs in understanding neuroscience or developing new methodologies. Eligible applicants include a wide range of organizations such as educational institutions, nonprofits, and tribal governments, with funding available up to $200,000 over two years. Interested parties should submit their applications by January 7, 2025, and can find additional information and application guidelines at the NIH website or contact grantsinfo@nih.gov for assistance.
    NINDS Exploratory Clinical Trials (UG3/UH3 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute of Neurological Disorders and Stroke (NINDS), is offering a funding opportunity for investigator-initiated exploratory clinical trials under the UG3/UH3 mechanism. This initiative aims to support Phase 1 and Phase 2 clinical trials that address critical questions related to neurological disorders, focusing on studies involving drugs, biologics, devices, and early interventions. The program emphasizes rigorous research design and encourages diverse and innovative research teams, with grants potentially spanning up to five years, beginning with a planning phase before transitioning to execution. Interested applicants can find more information and application details at the provided link, with a submission deadline of March 10, 2025, and no cost-sharing or matching requirement.
    NINDS Exploratory Clinical Trials for Small Business (R43/R44 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for small business concerns (SBCs) through the NINDS Exploratory Clinical Trials program (R43/R44), aimed at supporting investigator-initiated exploratory clinical trials related to neurological disorders. This program invites applications for studies that evaluate drugs, biologics, devices, or therapies, generating preliminary data to inform future clinical development, with a focus on enhancing diverse perspectives within research teams. Eligible U.S.-based SBCs can apply for funding caps of up to $295,924 for Phase I and $1,972,828 for Phase II, with applications due by September 5, 2026. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/pa-files/PAR-23-311.html.
    Development of Biomarkers or Biomarker Signatures for Neurological and Neuromuscular Disorders (R61/R33 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Development of Biomarkers or Biomarker Signatures for Neurological and Neuromuscular Disorders (R61/R33 Clinical Trial Optional)." This initiative aims to promote the discovery and early evaluation of candidate biomarkers that can facilitate the clinical development of neurotherapeutics and their application in clinical practice, focusing on both animal studies and preliminary human evaluations. The funding is structured as a phased R61/R33 award, where the R61 phase emphasizes proof-of-concept studies using human samples, while the R33 phase focuses on clinical validation for specified uses. Interested applicants, including various educational and community organizations, must submit their proposals by May 7, 2025, and can find additional details and application guidelines at the provided NIH link. For inquiries, applicants can contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov.
    Drug Discovery For Nervous System Disorders (R01 Clinical Trials Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity through the R01 Research Project Grant aimed at advancing drug discovery for nervous system disorders. This initiative focuses on the identification, design, synthesis, and preclinical testing of novel therapeutic compounds, particularly emphasizing innovative approaches to drug metabolism and pharmacokinetics, while excluding clinical trial applications. The program encourages high-risk, novel projects that aim to translate scientific research into effective treatments for conditions such as mental illness and substance use disorders. Interested applicants can find more information and guidelines in the NIH Grant Application Guide, with applications due by January 7, 2025. For inquiries, contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov.
    Translational Efforts to Advance Gene-based Therapies for Ultra-Rare Neurological and Neuromuscular Disorders (U01 - Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Translational Efforts to Advance Gene-based Therapies for Ultra-Rare Neurological and Neuromuscular Disorders" (U01), aimed at supporting Investigational New Drug (IND)-enabling studies and clinical trial planning for innovative gene-based therapeutics targeting ultra-rare diseases affecting fewer than 6,000 individuals. The program seeks to advance promising therapeutic candidates through robust proof-of-concept data and facilitate the submission of IND applications to the FDA, thereby addressing significant unmet medical needs within the ultra-rare disease community. Eligible applicants include higher education institutions, nonprofits, and governmental agencies, with a project period not exceeding two years and application deadlines ranging from October 2023 to February 2025. For further inquiries, interested parties can contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov, and additional details can be found at the provided NIH link.
    NINDS Exploratory Clinical Trials for Small Business (R41/R42 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "NINDS Exploratory Clinical Trials for Small Business (R41/R42 Clinical Trial Required)" aimed at supporting Small Business Concerns (SBCs) in conducting investigator-initiated exploratory clinical trials related to neurological disorders. This initiative encourages applications for Phase I and II studies focusing on drugs, biologics, devices, and therapies that align with the mission of the National Institute of Neurological Disorders and Stroke (NINDS), emphasizing the inclusion of a Plan for Enhancing Diverse Perspectives (PEDP) to foster innovation. The maximum funding amounts are $295,924 for Phase I and $1,972,828 for Phase II projects, with applications required to demonstrate readiness for eventual FDA regulatory approval. Interested applicants can begin submitting proposals on December 5, 2023, with the application deadline set for September 5, 2026; for further inquiries, contact NIH Grants Information at grantsinfo@nih.gov.